miR-375 modulates radiosensitivity of HR-HPV-positive cervical cancer cells by targeting UBE3A through the p53 pathway

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 2210-2217

  Song, Lili ^a   Liu, Shikai ^a   Zeng, Saitian ^a   Zhang, Liang ^a   Liv, Xia ^a  

^a CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

Human papillomavirus 16; Human papillomavirus 18; Uterine cervical neoplasms

Indexed keywords

MICRORNA 375; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3A; UNCLASSIFIED DRUG; MICRORNA; MIRN375 MICRORNA, HUMAN; RNA; TP53 PROTEIN, HUMAN; UBE3A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; BINDING ASSAY; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MTT ASSAY; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; WART VIRUS; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BINDING SITE; CASE CONTROL STUDY; GENE SILENCING; GENETICS; HELA CELL LINE; METABOLISM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHYSIOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS;

APOPTOSIS; BINDING SITES; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; MICRORNAS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RADIATION TOLERANCE; RNA, NEOPLASM; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 84938579671     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893859     Document Type: Article

References (27)

1. Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. Cancer J Clin, 2014; 64(1): 9–29
2. Rogers L, Siu SS, Luesley D et al: Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev, 2012; 5: CD007583
3. Waggoner SE: Cervical cancer. Lancet, 2003; 361(9376): 2217–25
4. Powell ME: Modern radiotherapy and cervical cancer. Int J Gynecol Cancer, 2010; 20(11 Suppl.2): S49–51
5. Frega A, Sopracordevole F, Scirpa P et al: The re-infection rate of high-risk HPV and the recurrence rate of vulvar intraepithelial neoplasia (VIN) usual type after surgical treatment. Med Sci Monit, 2011; 17(9): CR532–35
6. Dunne EF, Park IU: HPV and HPV-associated diseases. Infect Dis Clin North Am, 2013; 27(4): 765–78
7. Durst M, Gissmann L, Ikenberg H, zur Hausen H: A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA, 1983; 80(12): 3812–15
8. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 1993; 75(3): 495–505
9. Buyru N, Altinisik J, Isin M, Dalay N: p53 codon 72 polymorphism and HPV status in lung cancer. Med Sci Monit, 2008; 14(9): CR493–97
10. Concin N, Zeillinger C, Stimpfel M et al: p53-dependent radioresistance in ovarian carcinoma cell lines. Cancer Lett, 2000; 150(2): 191–99
11. Yang CF, Peng LX, Huang TJ et al: Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer Lett, 2014; 344(2): 260–71
12. Lindel K, Rieken S, Daffinger S et al: The transcriptional regulator gene E2 of the Human Papillomavirus (HPV) 16 influences the radiosensitivity of cervical keratinocytes. Radiat Oncol, 2012; 7: 187
13. Beskow C, Skikuniene J, Holgersson A et al: Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer, 2009; 101(5): 816–21
14. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004; 116(2): 281–97
15. Zhang B, Chen J, Ren Z et al: A specific miRNA signature promotes radioresistance of human cervical cancer cells. Cancer Cell Int, 2013; 13(1): 118
16. Ke G, Liang L, Yang JM et al: MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene, 2013; 32(25): 3019–27
17. Koh WJ, Greer BE, Abu-Rustum NR et al: Cervical cancer. J Natl Compr Canc Netw, 2013; 11(3): 320–43
18. Gartel AL, Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res,2005; 65(10): 3980–85
19. Li Y, Wang F, Xu J et al: Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol, 2011; 224(4): 484–95
20. Lajer CB, Garnaes E, Friis-Hansen L et al: The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer, 2012; 106(9): 1526–34
21. Xu Y, Jin J, Liu Y et al: Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2. PloS One, 2014; 9(7): e99516
22. Liu Y, Xing R, Zhang X et al: miR-375 targets the p53 gene to regulate cellular response to ionizing radiation and etoposide in gastric cancer cells. DNA Repair, 2013; 12(9): 741–50
23. Hong S, Noh H, Teng Y et al: SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia, 2014; 16(4): 279–90 e271–75
24. Wang F, Li Y, Zhou J et al: miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1. Am J Pathol, 2011; 179(5): 2580–88
25. Shen Y, Zhou J, Li Y et al: miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PloS One, 2014; 9(10): e109299
26. Jung HM, Phillips BL, Chan EK: miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14- 3-3zeta. Mol Cancer, 2014; 13: 80
27. Sah NK, Khan Z, Khan GJ, Bisen PS: Structural, functional and therapeutic biology of survivin. Cancer Lett, 2006; 244(2): 164–71